Advertisement
Advertisement
-
China /

Money & Wealth

Related Topics:
Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

China’s central-local fiscal flows should be parent-child relationship: adviser

China and Hong Kong should relax biotech listing rules, venture capitalist says

Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW